GlassScriptPhysician profile
Dhavalkumar B Patel
NPI 1053546846
$2,942.71
in general payments reported to CMS, 2019-2025
26 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $15.43 · 2021: $189 · 2022: $338 · 2023: $229 · 2024: $747 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $519.80 | 2021-2025 | Lifevest |
| Abiomed | $395.29 | 2024-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $276.00 | 2021-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $270.45 | 2019-2024 | Watchman Flx |
| Pfizer INC. | $260.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $186.65 | 2021-2025 | |
| Medtronic, INC. | $144.07 | 2022-2025 | Ffrangio, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $125.75 | 2021-2023 | Xarelto |
| Shockwave Medical, INC | $117.56 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kestra Medical Technology Services, INC. | $91.14 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $78.96 | 2023-2025 | Onpattro, Amvuttra |
| Amgen INC. | $73.63 | 2022-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.19 | 2019-2022 | |
| Penumbra, INC. | $47.70 | 2024 | Indigo System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $33.08 | 2024 | Uptravi, Opsumit |
| Cardiva Medical, INC. | $23.49 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Lilly USA, LLC | $23.44 | 2025 | Zepbound |
| Abbott Laboratories | $22.34 | 2021 | |
| Cvrx, INC. | $22.17 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $20.88 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $19.66 | 2021 | |
| Novo Nordisk INC | $18.63 | 2021 | |
| Teleflex LLC | $16.95 | 2024 | Turnpike |
| Merck Sharp & Dohme LLC | $16.65 | 2023 | Verquvo |
| Cardiovascular Systems INC. | $15.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhavalkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.